PRM10 Exploration of heterogeneity in distributed research network drug safety analyses  by Hansen, R.A. et al.
A14 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
incorporated HbA1c<7% at endpoint, reflecting ADA recommendations; others 
included no weight gain (NWG), no hypoglycemia (NH), SBP<130, and LDL<2.6. 
The averge proportion achieving 2-component CEPs at 26 weeks was 36% 
(median=35%); an average of 17% (median=13%) achieved 3-component CEPs. 
One 3-component CEP (HbA1c+NWG+NH) had rates for both 26 and 52 weeks. 
The proportion achieving this CEP increased 23% between weeks 26 and 52. 
Proportions meeting CEPs increased by 67%-150% in patients with baseline 
HbA1c levels >8.0%. CONCLUSIONS: CEPs have been used to a limited extent as 
indicators of clinical outcomes in type-2 diabetes trials. More research is 
required to identify optimal CEPs.  
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MEDICATION ADHERENCE FOR CLOZAPINE VERSUS OTHER SECOND-
GENERATION ANTIPSYCHOTIC DRUGS IN PATIENTS WITH SCHIZOPHRENIA  
Velligan DI1, Carroll CA2, Lage MJ3 
1University of Texas Health Sciences Center San Antonio, San Antonio, TX, USA, 2Teva 
Pharmaceuticals, Kansas City, MO, USA, 3HealthMetrics Outcomes Research, Delray Beach, FL, 
USA  
OBJECTIVES: To compare adherence rates and health care utilization for 
clozapine versus other second-generation antipsychotics used as monotherapy 
in the treatment of schizophrenia. METHODS: The study was an observational, 
retrospective analysis of medical and pharmacy claims from a national 
insurance organization with approximately 14 million enrollees, conducted using 
the i3 InvisionTM Data Mart database for dates of service from January 2006 
through December 2009. Study patients had >1 pharmacy claim for a second-
generation antipsychotic (study drugs: apiprazole, clozapine, olanzapine, 
paliperidone, quetiapine, risperidone, or ziprasidone) with no pharmacy claims 
for any study drug during a 6-month preperiod prior to the initial (index) claim. 
All patients met the following criteria: no pharmacy claims for any second-
generation antipsychotic other than the index medication during the 90 days 
following the index claim; aged 18 to 64 years; continuously enrolled from the 
preperiod through 12 months after the index date (postperiod); and >1 medical 
claim with a diagnosis of schizophrenic disorder (ICD-9-CM=295.xx) in either 
period. Logistic regression analyses modeled binomial measures of postperiod 
medication possession ratio (MPR) for the index drug (>80%=adherent) and 
postperiod hospitalizations and emergency room (ER) use in 3 categories: all-
cause, mental disorder-related (ICD-9-CM=290.xx-319.xx), and schizophrenia 
related (ICD-9-CM=295.xx), controlling for patient demographics, preperiod 
hospitalization and ER use, and preperiod comorbidities. RESULTS: Mean MPRs 
for the sample (N=19,804) were 0.78 for clozapine, 0.62 for quetiapine, and 0.42-
0.49 for the remaining study drugs. In logistic regression analyses, the odds of 
MPR >80% were lower for all study drugs compared with clozapine (odds ratio 
[OR]=0.603, 95% confidence interval=0.483-0.754 for quetiapine and ORs=0.306 to 
0.390 for remaining drugs). CONCLUSIONS: Compared with other second-
generation antipsychotics, treatment with clozapine is associated with better 
adherence and equal or less all-cause and disease-specific hospital care 
utilization. These findings should be interpreted in light of the benefits and risks 
of all antipsychotic drugs.  
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REVIEW  
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OBJECTIVES: To evaluate the methods and results of published indirect 
comparison meta-analyses of boceprevir and telaprevir for genotype 1 hepatitis 
C infection, and to identify methodological issues that can explain the 
discrepancies in the results of these meta-analyses. METHODS: We searched 
MEDLINE and EMBASE for indirect comparisons of boceprevir and telaprevier for 
genotype 1 hepatitis C infection. Following the PRISMA guidelines, we extracted 
a large set of methodological items. These comprised of inclusion/exclusion 
criteria, information sources, classification of treatments, and analytic 
approaches. RESULTS: We identified 4 indirect comparisons. Despite similarly 
stated eligibility criteria and objectives across these indirect comparisons, we 
identified discrepancies in the selection of pooled arms and the analytic 
approaches used, which are most likely to have influenced the differences in the 
estimated treatment effects. While three of the four studies stratified their 
analyses by standard-duration therapy (SDT) arms and response-guided therapy 
(RGT) arms of comparable dose and length of treatment, one study pooled both 
SDT and RCT therapy together. Three of the four studies used a Bayseian 
approach, and one used an adjusted Bucher approach. The use of random and 
fixed effects models also differed between the studies. Furthermore, the type of 
peg-interferon used (alpha-2a versus alpha-2b) was only given full consideration 
in 2 of the included studies. Finally, although no study observed statistical 
differences between boceprevir and telaprevir, the estimated treatment effects 
differed. CONCLUSIONS: The identified methodological shortcomings and 
inconsistencies most likely explain the observed discrepancies in findings 
between the indirect comparisons. Consideration of the methodological 
differences is necessary when interpreting the results of these studies.  
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OBJECTIVES: The long-term care needs in patients under maintenance 
hemodialysis (HD) have not been explored before. To estimate the changes of 
proportion for different functional disabilities along time after beginning HD and 
the lifelong care needs. METHODS: We used a population-based cohort 
consisting of 84,657 incident patients under maintenance HD in Taiwan between 
1998 and 2009 to calculate the survival functions. The Barthel Index (BI) was used 
to measure functional disability levels cross-sectionally in 1272 HD patients 
recruited from multiple HD centers. A BI score less than 50 was considered a 
severe disability. The kernel-smoothing method was used to estimate the 
dynamic changes of different functional disability. The survival function was 
extrapolated to lifetime by a semi-parametric method and then multiplied with 
proportions of different kinds of functional disabilities over time to obtain the 
lifetime care needs after age stratification. RESULTS: On average, patients under 
maintenance HD had 6.5 (± 0.1) years without disability, 1.9 (± 0.1) years with 
moderate disability, and 1.3 (± 0.1) years with severe disability. The most 
common needs for assistance throughout their lifetimes were stair-climbing and 
bathing which were 2.8 years and 1.6 years, respectively. HD patients were 
expected to have about 3 years living with disabilities for all age groups above 35; 
however, old patients showed higher proportions of functional disabilities. 
CONCLUSIONS: HD patients are in need of long term care. The older the age, the 
higher the proportions that need different care services.  
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COMPARISON OF TRADITIONAL STATIN ADHERENCE MEASUREMENT WITH 
AN ENHANCED METHOD ALLOWING FOR MORE INCLUSIVE PATIENT 
MEASUREMENT  
Jiang JZ, Taitel M, Rudkin K, Fensterheim L 
Walgreen Co., Deerfield, IL, USA  
OBJECTIVES: The methodology used to estimate medication adherence typically 
identifies patients with sold scripts during a specified index period. We propose 
a new method for calculating medication adherence that expands the patient 
population by including patients who filled medications and those who did not 
fill medication, but were expected to fill or had available medication during the 
index period. METHODS: During the index period of January 2011, patients 
filling, expected to fill, or who had statin medication on hand from a national 
retail pharmacy were included in the study. 12-month adherence metrics were 
calculated using the traditional method as well as the enhanced method using 
proportion of days covered (PDC). Patients were also segmented by refill 
behaviors such as new, returning, late, and continuing therapy and expected 
non-fillers. RESULTS: We identified 2,278,751 statin patients using the traditional 
method. The enhanced method identified 556,525 additional expected non-filler 
patients and 815,775 patients with available medication. Of the additional 
patients from the enhanced method, 67% eventually refilled their prescriptions 
in the subsequent 2 months. The enhanced method had an overall 12-month 
adherence of 0.693 compared to 0.733 for the traditional method. PDCs ranged 
from (0.420 - 0.794) depending on patient segment. These results are from a 
single pharmacy chain. Patients switching pharmacies will not be fully captured 
in these results. CONCLUSIONS: This enhanced method for measuring 
adherence identifies a more complete patient population of those at risk for 
hyperlipidemia because it accounts for all patients during the index period. 
Although the additional patients could be included using the traditional method 
within a 3-month index period, the new method captures all patients who are on 
therapy during a shorter index period. This enhanced method allows for quicker 
analysis to support interventions that improve patient’s adherence.  
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OBJECTIVES: Distributed data networks are an expanding focus of drug safety 
research. However, interpreting results of distributed analyses is challenging 
when treatment effects are heterogeneous. We assessed heterogeneity of 
treatment effects and explored factors influencing heterogeneity using 
experimental results from the Observational Medical Outcomes Partnership 
(OMOP). METHODS: OMOP evaluated risk of eight health outcomes across nine 
drug groups, replicating analyses across eight data sources using a common data 
model. We focused on the OMOP propensity score analyses and assessed 
heterogeneity using meta-analysis and I-squared statistics. Plots of the 
relationship between influence on overall results and contribution to overall 
heterogeneity identified influential data sources. Summary-level data source 
characteristics were examined to identify potential factors with high variability 
that could be influencing results. Exploratory meta-regression further assessed 
the relationship of summary-level characteristics with heterogeneity using risk 
of bleeding with warfarin and un-related negative controls (antibiotics, 
benzodiazepines, and tricyclic antidepressants). RESULTS: Heterogeneity, as 
measured by the I-squared statistic, ranged from 0-99% across the drug-outcome 
pairs studied. In general, heterogeneity generally was lower for analyses of 
angioedema (0-71%) and aplastic anemia (0-84%) and higher for acute liver injury 
(74-91%) and bleeding (78-99%). Plots of the relationship between influence on 
overall results and contribution to heterogeneity illustrated limited data source 
clustering, which is an indicator that heterogeneity was not driven by a single 
dataset but rather was unique to the drug and outcome being assessed. 
Exploratory meta-regression identified many variables influencing 
heterogeneity, but was unable to accurately identify specific factors that were 
most influential. CONCLUSIONS: Distributed data network drug safety analyses 
are challenging to interpret in the face of heterogeneity. A formal assessment of 
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A15 
 
 
heterogeneity should be conducted, and approaches illustrated here can be 
useful to explore heterogeneity. Further evaluation of the value of patient-level 
as opposed to summary-level data in heterogeneity assessment is needed.  
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OBJECTIVES: The defining characteristics of a disease condition are the same 
across all countries. Therefore, we hypothesize that when assessing a new 
treatment, via a clinical trial, we would expect different countries to value the 
same outcomes irrespective of where the trial was completed. We chose three 
disease conditions that are identified by exact biomarkers to test this hypothesis. 
METHODS: We collected all open, actively enrolling, phase III drug studies from 
www.clinicaltrials.gov for Multiple Sclerosis, Hepatitis C, and HIV. After 
eliminating non-interventional studies and studies with missing information, we 
were left with 39 Multiple Sclerosis, 33 HIV, and 40 Hepatitis C trials. We defined 
three study locations: “U.S. only,” “ex-U.S. only,” and “U.S. and ex-U.S.” Among 
Multiple Sclerosis studies, 13 were U.S.-only, 15 ex-U.S. only, and 11 were U.S. 
and ex-U.S. Among HIV studies, 3 were U.S.-only, 19 ex-U.S. only, and 11 were 
U.S. and ex-U.S. Among Hepatitis C studies none were U.S. only, 23 ex-U.S., and 
17 were U.S. and ex-U.S. Fisher’s exact test was used to examine associations 
between study locations and types of clinical trial outcomes measured. 
RESULTS: We found no statistically significant differences in the outcomes 
evaluated by Multiple Sclerosis studies or HIV studies. Four of the 11 Hepatitis C 
outcome categories evaluated different outcomes depending on location: 
Sustained Virologic Response Week 12 (p-value 0.0011), Laboratory (p-value 
0.0525), AEs (p-value 0.0235), and Safety (p-value 0.0227). CONCLUSIONS: Our 
results support our hypothesis for two of the three conditions we examined, 
Multiple Sclerosis and HIV. However, for Hepatitis C, we found that clinical trials 
outcomes differ by location. The recent surge in development in Hepatitis C 
drugs may explain the discrepancy; however, further research and more data is 
needed.  
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NETWORK META-ANALYSIS OF SURVIVAL DATA. THE VALUE OF 
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OBJECTIVES: Network meta-analysis of published survival data are often based 
on the reported hazard ratio. In this paper we illustrate the value of 
reconstructing data from published Kaplan-Meier curves to perform network 
meta-analysis. METHODS: Published Kaplan-Meier survival curves of trials 
evaluating different interventions for non-small-cell lung cancer were digitally 
scanned. Next, a dataset was created with for each treatment of each trial the 
number of events and number of patients at risk for multiple short time intervals 
over the complete follow-up period. Two types of network meta-analyses were 
performed: 1) For each publication for which no hazard ratio was reported, a 
hazard ratio was estimated based on the scanned curves. Subsequently, all 
hazard ratios of all trials were synthesized with a network meta-analysis model 
assuming a constant hazard ratio (2-step approach); 2) A network meta-analysis 
of the constructed data of the Kaplan-Meier curves of all trials was performed (1-
step approach). RESULTS: The 1-step approach showed that the assumption of a 
constant hazard ratio was not valid for the used dataset. The results of the 1-step 
network meta-analysis could be presented as pooled parametric survival curves. 
CONCLUSIONS: Reconstructing data from published Kaplan-Meier curves allows 
for the inclusion of all relevant studies in a network meta-analysis, even if 
hazard ratios are not reported. Furthermore, it allows for network meta-analysis 
models that do not rely on the assumption of a constant hazard ratio, which 
have great value for cost-effectiveness models.  
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OBJECTIVES: In the last decade, network meta-analysis (mixed treatment 
comparison meta-analysis) has been introduced as a generalization of pair-wise 
meta-analysis. Many randomized controlled trials (RCTs) report treatment effect 
estimates for the outcomes of interest at multiple time points. In this paper we 
compare different methods for network meta-analysis of repeated measures. 
METHODS: Different network meta-analysis models for the synthesis of study 
level data of RCTs evaluating interventions for osteoarthritis were compared: 
separate network meta-analyses per time point; models assuming a linear 
development of treatment effects over time; network meta-analysis models with 
fractional polynomials; and network meta-analysis with splines. All analyses 
were performed in a Bayesian framework. RESULTS: The primary limitation of 
multiple network meta-analyses of study level data by time point was  
the inconsistency in the used evidence base for each time point. Of the models 
that estimate a relationship between outcome and time, fractional polynomials  
had an advantage over splines for the current dataset because the former  
model resulted in more stable parameter estimates and still  
provided sufficient fit to the data. CONCLUSIONS: To understand  
treatment effects over time, reported treatment effects of RCTs need to be 
synthesized simultaneously. Network meta-analysis of longitudinal study level 
data with second order fractional polynomials are a very useful approach to 
evaluate trends of treatment effects over time when there is not too much 
variation in treatment effects from one time point to the next. An additional 
advantage is that the methodology can handle differences in follow-up time 
across trials.  
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OBJECTIVES: 1) To Study the effect of L-carnitine supplementation on behavioral 
symptoms in autistic children; 2) Study the effect of l-Carnitine supplementation 
on Acyl-Carnitine profile of Autistic children; 3) Detect possible correlation 
between the blood Carnitine status and Autistic behavior; and 4) Tolerability 
assessment of l-carnitine supplementation. METHODS: Thirty children 
diagnosed with autism were randomly assigned to receive (100 mg/kg 
bodyweight/day) of liquid l-carnitine (n=16) or placebo (n=14) for 6 months. 
Measurements included changes in childhood autism rating scale (CARS) form 
and free and total carnitine levels using tandem mass spectrometry. RESULTS: 
Results showed significant improvement in CARS scores (P-groups <0.001) and  
(P-overtime= 0.006), with statistically significant differences in free carnitine 
levels (P=0.027) and total carnitine levels (P=0.036 ) . There was no correlation 
between baseline free and total carnitine levels with changes in CARS scores 
from zero to 6 months (r > 0.5 , P> 0.05) and generally L-carnitine therapy was 
well tolerated. In conclusion, L-carnitine therapy (100 mg/kg-bodyweight/day) 
administered for 6 months significantly improved the autism severity, but 
subsequent studies are recommended. CONCLUSIONS: 1) Significant differences 
were found in free and total carnitine levels after therapy; 2) Clinically, L-
carnitine supplementation improves autism severity; 3) L-carnitine therapy was 
well tolerated; and 4) L-carnitine supplements may be given as part of autism 
treatment regimen.  
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PLEASE PASS THE NEW TEMPLATE: DEVELOPING NON-INTERVENTIONAL 
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Oberthur Johnson L1, Zarotsky V2, Spannheimer A3, Gulyas SW1, Clark SJ4 
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OBJECTIVES: Post-authorization interventional clinical trials (CT) and non-
interventional clinical studies (NIS) are increasingly used to evaluate safety and 
other outcomes in real-world settings. Previously, NIS clinical study report (CSR) 
templates used International Society for Pharmacoepidemiology (ISPE; 
www.pharmacoepi.org) reporting guidelines and/or were modified from 
International Conference on Harmonisation (ICH) E3 guidelines. Resulting CSR 
templates may not have contained adequate instructions to develop CSRs for 
regulatory review and subsequent corresponding manuscripts. We reviewed 
various published documents and developed robust NIS CSR templates for use in 
regulatory submission. METHODS: Guidelines reviewed included ISPE (based on 
FDA guidance and EU documents) and Guideline on Good Pharmacovigilance 
Practices – module VIII (www.ema.europa.eu), which describes post-
authorization safety studies (PASS) and updated CSR guidelines, following 
implementation of revised pharmacovigilance legislation in July 2012. For NIS 
manuscripts, STROBE (STrengthening the Reporting of oBservational studies in 
Epidemiology) guidelines (www.strobe-statement.org) were reviewed. We also 
reviewed other NIS-related documents, as well as interventional CT-related 
documents, including ICH CSR guidelines and CONSORT (CONsolidated 
Standards of Reporting Trials) or other design-specific guidelines (www.equator-
network.org) for writing corresponding manuscripts. Additional instructional 
and preferred/optional text was developed for the templates. RESULTS: Overall, 
PASS guidelines provided additional NIS details and were aligned with most 
regulatory sections common in ISPE and aligned closely with STROBE 
statements. ISPE guidelines provided few details for CSR template development. 
Other guidelines and a literature review provided additional CSR template text 
and the inclusion of STROBE–based text supported development of manuscripts. 
By utilizing multiple document sources, new templates were developed that 
contained improved instructions and text while meeting regulatory 
requirements. Furthermore, decision trees were included to support the 
numerous types of NIS study designs. CONCLUSIONS: By aligning CSR guidelines 
with design-specific publication guidelines, template quality was improved for 
regulatory submissions and authors could easily identify important report 
content when writing peer-reviewed publications.  
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OBJECTIVES: To assess the referral patterns and impact for FDG PET/CT for 
treatment management, and to determine the most common metastatic sites in 
breast cancer patients. METHODS: Retrospective analysis was performed on 
2,500 scans reported in Max hospital from November 2009 to March 2012, scans 
for breast cancer patients were separated out (500 scans). Medical records of 122 
consecutive breast cancer patients were retrospectively reviewed. Referral 
categories for PET/CT in breast cancer patients were: Diagnosis, Staging, 
Restaging, Early treatment response evaluation (after 3 cycles of chemotherapy), 
late treatment response evaluation (after 6 cycles of chemotherapy), and 
Radiation therapy response evaluation. RESULTS: PET/CT was mostly used for 
